{"id":350495,"date":"2025-08-25T19:29:59","date_gmt":"2025-08-25T19:29:59","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-insmed-incorporated\/"},"modified":"2025-08-25T19:29:59","modified_gmt":"2025-08-25T19:29:59","slug":"how-to-buy-insmed-incorporated","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/","title":{"rendered":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-350495","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Insmed Incorporated (INSM) hisselerini g\u00fcncel fiyat\u0131 $131.88 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu yenilik\u00e7i biyofarmas\u00f6tik \u015firket i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Insmed Incorporated (INSM) hisselerini g\u00fcncel fiyat\u0131 $131.88 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu yenilik\u00e7i biyofarmas\u00f6tik \u015firket i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Nadir akci\u011fer hastal\u0131klar\u0131 tedavilerine adeta yeni bir soluk getiren bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Insmed Incorporated (sembol: INSM), t\u0131bbi yenilik ve yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. FDA onaylar\u0131n\u0131 birka\u00e7 hafta \u00f6nce alarak, bu biyoteknoloji oyuncusu hem sa\u011fl\u0131k uzmanlar\u0131n\u0131n hem de ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar\u0131n dikkatini \u00e7ekiyor. INSM'nin neden bir sonraki ak\u0131ll\u0131 yat\u0131r\u0131m hamleniz olabilece\u011fini birlikte ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Nadir akci\u011fer hastal\u0131klar\u0131 tedavilerine adeta yeni bir soluk getiren bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Insmed Incorporated (sembol: INSM), t\u0131bbi yenilik ve yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. FDA onaylar\u0131n\u0131 birka\u00e7 hafta \u00f6nce alarak, bu biyoteknoloji oyuncusu hem sa\u011fl\u0131k uzmanlar\u0131n\u0131n hem de ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar\u0131n dikkatini \u00e7ekiyor. INSM'nin neden bir sonraki ak\u0131ll\u0131 yat\u0131r\u0131m hamleniz olabilece\u011fini birlikte ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Insmed Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Insmed Incorporated (INSM), NASDAQ'ta <strong>$131.88<\/strong> fiyat\u0131yla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>30 Ekim 2025<\/strong> kesinlikle kritik bir tarih\u2014Insmed bu tarihte 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak, bu raporlar biyoteknoloji hisseleri i\u00e7in \u00f6nemli hareketler yaratm\u0131\u015ft\u0131r.<\/p>  <h3>FDA Onay\u0131n\u0131n 12 A\u011fustos 2025'te INSM Hissesini Nas\u0131l Hareketlendirdi\u011fi<\/h3> <p>Son at\u0131l\u0131mlar\u0131na piyasa tepkisi olduk\u00e7a belirgindi\u2014INSM, devrim niteli\u011findeki bron\u015fektazi ilac\u0131 BRINSUPRI'nin FDA onay\u0131n\u0131 takiben hemen <strong>%4.6<\/strong> art\u0131\u015fla $118.09 seviyesine y\u00fckseldi<a href=\"https:\/\/www.ainvest.com\/news\/insmed-surges-4-6-fda-approval-breakthrough-momentum-sustain-2508\/\">(AINvest)<\/a>. Hisse, o seansta 52 haftal\u0131k en y\u00fcksek seviyesi olan $120.50'yi g\u00f6rd\u00fc ve yat\u0131r\u0131mc\u0131lar\u0131n bu d\u00f6n\u00fcm noktas\u0131na ne kadar g\u00fcvendi\u011fini g\u00f6sterdi.<\/p>  <h3>Tarihsel Kazan\u00e7 Etkisi Deseni<\/h3> <ul> <li>\u015eubat 2025: 4. \u00e7eyrek kazan\u00e7lar\u0131 iki hafta i\u00e7inde %15'lik bir ralliyi tetikledi<\/li> <li>A\u011fustos 2024: Klinik deneme sonu\u00e7lar\u0131 tek g\u00fcnde %22'lik s\u0131\u00e7rama yaratt\u0131<\/li> <li>May\u0131s 2024: Olumlu Faz 3 verileri b\u00fcy\u00fck bir %150 art\u0131\u015fa neden oldu<a href=\"https:\/\/www.genengnews.com\/topics\/drug-discovery\/stockwatch-after-fda-approval-analysts-predict-blockbuster-sales-for-insmed-drug\/\">(GEN News)<\/a><\/li> <li>Kas\u0131m 2023: Ortakl\u0131k duyurusu %8 kazan\u00e7 sa\u011flad\u0131<\/li> <li>A\u011fustos 2023: FDA ba\u015fvuru haberi %12 momentum yaratt\u0131<\/li> <\/ul> <p>Desen a\u00e7\u0131k: olumlu klinik ve d\u00fczenleyici haberler patlay\u0131c\u0131 hareketler yarat\u0131rken, kazan\u00e7 raporlar\u0131 s\u00fcrd\u00fcr\u00fclebilir momentum sa\u011flar.<\/p>  <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden Zaferine<\/h3> <p>INSM'nin \u015eubat 2025'ten bu yana yolculu\u011fu ola\u011fan\u00fcst\u00fc oldu. Hisse bu d\u00f6nemde <strong>%37.73<\/strong> de\u011fer kazand\u0131<a href=\"https:\/\/www.barchart.com\/stocks\/quotes\/insm\/performance\">(Barchart)<\/a>, ancak as\u0131l hikaye dramatik toparlanmada yat\u0131yor:<\/p> <ul> <li><strong>\u015eubat-Mart 2025<\/strong>: $85-95 aral\u0131\u011f\u0131nda i\u015flem g\u00f6rerek taban olu\u015fturdu<\/li> <li><strong>9 Nisan 2025<\/strong>: D\u00f6nemin en d\u00fc\u015f\u00fck seviyesi olan $60.40'a geriledi\u2014maksimum korku an\u0131<\/li> <li><strong>May\u0131s-Haziran 2025<\/strong>: $75-85 aral\u0131\u011f\u0131na istikrarl\u0131 toparlanma<\/li> <li><strong>Temmuz 2025<\/strong>: $95 \u00fczeri k\u0131r\u0131l\u0131m, momentum art\u0131yor<\/li> <li><strong>A\u011fustos 2025<\/strong>: FDA onay kataliz\u00f6r\u00fc hisseyi mevcut $131.88 seviyesine f\u0131rlatt\u0131<\/li> <\/ul> <p>Nisan dip seviyesinden itibaren hisse inan\u0131lmaz bir <strong>%84.21<\/strong> y\u00fckseldi<a href=\"https:\/\/www.barchart.com\/stocks\/quotes\/insm\/performance\">(Barchart)<\/a>, kataliz\u00f6r odakl\u0131 biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n g\u00fcc\u00fcn\u00fc g\u00f6steriyor.<\/p>  <h3>Bu Toparlanman\u0131n \u00d6nemi<\/h3> <p>V \u015feklindeki desen g\u00fc\u00e7l\u00fc kurumsal g\u00fcveni i\u015faret ediyor. Biyoteknoloji hisseleri diplerden b\u00f6yle sert s\u0131\u00e7rad\u0131\u011f\u0131nda, genellikle ak\u0131ll\u0131 paran\u0131n b\u00fcy\u00fck bir geli\u015fmenin yakla\u015ft\u0131\u011f\u0131n\u0131 bildi\u011fi anlam\u0131na gelir.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 (Y\u0131l Sonu)<\/strong>: $145-160<br> Son FDA onay\u0131 \u00e7eyreklik gelir b\u00fcy\u00fcmesini desteklemeli, analistler ortalama hedefi <strong>$139.31<\/strong> olarak tahmin ediyor<a href=\"https:\/\/stockanalysis.com\/stocks\/insm\/forecast\/\">(StockAnalysis)<\/a>. Anahtar tarih 30 Ekim'deki 3. \u00e7eyrek kazan\u00e7lar\u0131\u2014g\u00fc\u00e7l\u00fc re\u00e7ete say\u0131lar\u0131 fiyat\u0131 \u00fcst seviyelere ta\u015f\u0131yabilir.<\/li> <li><strong>2026<\/strong>: $180-210<br> BRINSUPRI'nin tam y\u0131l ticarile\u015ftirilmesi ve Avrupa ile \u0130ngiltere'de uluslararas\u0131 lansmanlar. \u0130lac\u0131n tahmini $5 milyar zirve sat\u0131\u015f potansiyelinin yar\u0131s\u0131n\u0131 bile yakalamas\u0131 durumunda<a href=\"https:\/\/www.genengnews.com\/topics\/drug-discovery\/stockwatch-after-fda-approval-analysts-predict-blockbuster-sales-for-insmed-drug\/\">(GEN News)<\/a>, hisse \u00f6nemli \u00f6l\u00e7\u00fcde yeniden de\u011ferlenmeli.<\/li> <li><strong>2028<\/strong>: $250-300<br> Bu noktada birden fazla \u00fcr\u00fcn gelir katk\u0131s\u0131 sa\u011flamal\u0131. Akci\u011fer hipertansiyonu i\u00e7in geli\u015ftirdikleri TPIP adl\u0131 ila\u00e7 ticarile\u015febilir ve ek gelir kaynaklar\u0131 yaratabilir.<\/li> <li><strong>2030<\/strong>: $350-400+<br> K\u00fcresel geni\u015fleme ve mevcut ila\u00e7lar i\u00e7in potansiyel yeni endikasyonlar. Uygulama g\u00fc\u00e7l\u00fc kal\u0131rsa, INSM milyarlarca dolarl\u0131k gelir \u015firketi olabilir.<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM \u00f6nerisi. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 takip etmeli.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Pipeline\u2019daki herhangi bir aksama hisseyi olumsuz etkileyebilir<\/li> <li><strong>D\u00fczenleyici engeller<\/strong>: Uluslararas\u0131 onaylarda gecikmeler veya k\u0131s\u0131tlamalar olabilir<\/li> <li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri \u00fcst\u00fcn tedaviler geli\u015ftirebilir<\/li> <li><strong>Nakit t\u00fcketimi<\/strong>: 2025 2. \u00e7eyrekte 321.7 milyon $ net zarar bildirdiler<a href=\"https:\/\/www.prnewswire.com\/news-releases\/insmed-reports-second-quarter-2025-financial-results-and-provides-business-update-302523543.html\">(PR Newswire)<\/a><\/li> <li><strong>Piyasa volatilitesi<\/strong>: Biyoteknoloji hisseleri genellikle \u00f6ng\u00f6r\u00fclemezdir<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>FDA onay\u0131 al\u0131nd\u0131<\/strong>: BRINSUPRI art\u0131k ticari olarak mevcut<\/li> <li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>: Haziran 2025 itibar\u0131yla 1.9 milyar $<a href=\"https:\/\/www.prnewswire.com\/news-releases\/insmed-reports-second-quarter-2025-financial-results-and-provides-business-update-302523543.html\">(PR Newswire)<\/a><\/li> <li><strong>Gelir b\u00fcy\u00fcmesi<\/strong>: ARIKAYCE i\u00e7in y\u0131ll\u0131k %11-17 b\u00fcy\u00fcme \u00f6ng\u00f6r\u00fcl\u00fcyor<\/li> <li><strong>Analist deste\u011fi<\/strong>: 19 analistten 18\u2019i Al veya G\u00fc\u00e7l\u00fc Al derecelendirmesi veriyor<a href=\"https:\/\/stockanalysis.com\/stocks\/insm\/forecast\/\">(StockAnalysis)<\/a><\/li> <li><strong>Piyasa m\u00fcnhas\u0131rl\u0131\u011f\u0131<\/strong>: Bron\u015fektazi tedavisinde ilk hareket eden avantaj\u0131<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5\u2019inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Ortalama maliyetle al\u0131m yap\u0131n<\/strong>: T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a al\u0131n<\/li> <li><strong>30 Ekim i\u00e7in uyar\u0131 kurun<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 m\u00fckemmel giri\u015f noktas\u0131 olabilir<\/li> <li><strong>Re\u00e7ete verilerini takip edin<\/strong>: Ayl\u0131k re\u00e7ete say\u0131lar\u0131 kritik olacak<\/li> <li><em>Deneyimli yat\u0131r\u0131mc\u0131lardan esprili tavsiye<\/em>: \"Biyoteknoloji hisseleriyle ticaret yapmak fl\u00f6rt etmek gibidir\u2014bazen peri masal\u0131 sonu ya\u015fars\u0131n\u0131z, bazen de d\u00fc\u011f\u00fcn salonunda kal\u0131rs\u0131n\u0131z. Her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!\"<\/li> <\/ol>  <h2>\u2705 Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir i\u015flem platformu se\u00e7in<\/td> <td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td> <td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td> <td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 $131.88 (25 A\u011fustos itibar\u0131yla) kontrol edin<\/td> <\/tr> <tr> <td>4<\/td> <td>Sipari\u015finizi verin<\/td> <td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 takip edin<\/td> <td>\u00d6nemli hareketli ortalamalar i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td> <\/tr> <\/tbody> <\/table>  <h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Uygun?<\/h3> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum depozito sadece $5<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyip hemen i\u015flem yapmaya ba\u015flayabilirsiniz<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto para, e-c\u00fczdanlar ve banka kartlar\u0131 dahil<\/li> <li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131 m\u00fcmk\u00fcn<\/strong>\u2014INSM gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <\/ul>  <h2>\ud83c\udf0d 2025'te Insmed: Nadir Hastal\u0131k Tedavisinde D\u00f6n\u00fc\u015f\u00fcm<\/h2> <p>Insmed ilgin\u00e7 bir kav\u015fakta duruyor. Klinik a\u015famadaki biyoteknoloji \u015firketinden FDA onay\u0131yla ticarile\u015fen bir \u015firkete ba\u015far\u0131l\u0131 bir ge\u00e7i\u015f yapt\u0131<a href=\"https:\/\/www.ajmc.com\/view\/brensocatib-becomes-first-fda-approved-therapy-for-bronchiectasis\">(AJMC)<\/a>. \u00d6zellikle yakla\u015f\u0131k 110.000 Amerikal\u0131y\u0131 etkileyen kistik fibrozis d\u0131\u015f\u0131 bron\u015fektazi gibi nadir akci\u011fer hastal\u0131klar\u0131na odaklanmalar\u0131, s\u0131n\u0131rl\u0131 rekabetin oldu\u011fu ancak hasta ihtiyac\u0131n\u0131n y\u00fcksek oldu\u011fu \u00f6zel bir ni\u015fte konumlanmalar\u0131n\u0131 sa\u011fl\u0131yor.<\/p> <p>\u015eirketin Haziran 2025'te ger\u00e7ekle\u015ftirdi\u011fi 750 milyon dolarl\u0131k halka arz<a href=\"https:\/\/investor.insmed.com\/2025-06-11-Insmed-Announces-Pricing-of-750-Million-Public-Offering-of-Common-Stock\">(Insmed Investor)<\/a>, BRINSUPRI'nin ticarile\u015ftirilmesi i\u00e7in yeterli kaynak sa\u011flarken di\u011fer pipeline varl\u0131klar\u0131n\u0131n geli\u015ftirilmesine devam edilmesini m\u00fcmk\u00fcn k\u0131ld\u0131.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Insmed'in BRINSUPRI'si, analistlerin bekledi\u011finden %10 daha y\u00fcksek olan y\u0131ll\u0131k 88.000 $'l\u0131k premium bir fiyat etiketiyle onay ald\u0131<a href=\"https:\/\/www.genengnews.com\/topics\/drug-discovery\/stockwatch-after-fda-approval-analysts-predict-blockbuster-sales-for-insmed-drug\/\">(GEN News)<\/a>. Bu fiyatlama g\u00fcc\u00fc, piyasan\u0131n yenilik\u00e7i nadir hastal\u0131k tedavilerine verdi\u011fi \u00f6nemli de\u011feri g\u00f6steriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Insmed Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Insmed Incorporated (INSM), NASDAQ&#8217;ta <strong>$131.88<\/strong> fiyat\u0131yla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>30 Ekim 2025<\/strong> kesinlikle kritik bir tarih\u2014Insmed bu tarihte 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak, bu raporlar biyoteknoloji hisseleri i\u00e7in \u00f6nemli hareketler yaratm\u0131\u015ft\u0131r.<\/p>\n<h3>FDA Onay\u0131n\u0131n 12 A\u011fustos 2025&#8217;te INSM Hissesini Nas\u0131l Hareketlendirdi\u011fi<\/h3>\n<p>Son at\u0131l\u0131mlar\u0131na piyasa tepkisi olduk\u00e7a belirgindi\u2014INSM, devrim niteli\u011findeki bron\u015fektazi ilac\u0131 BRINSUPRI&#8217;nin FDA onay\u0131n\u0131 takiben hemen <strong>%4.6<\/strong> art\u0131\u015fla $118.09 seviyesine y\u00fckseldi<a href=\"https:\/\/www.ainvest.com\/news\/insmed-surges-4-6-fda-approval-breakthrough-momentum-sustain-2508\/\">(AINvest)<\/a>. Hisse, o seansta 52 haftal\u0131k en y\u00fcksek seviyesi olan $120.50&#8217;yi g\u00f6rd\u00fc ve yat\u0131r\u0131mc\u0131lar\u0131n bu d\u00f6n\u00fcm noktas\u0131na ne kadar g\u00fcvendi\u011fini g\u00f6sterdi.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Deseni<\/h3>\n<ul>\n<li>\u015eubat 2025: 4. \u00e7eyrek kazan\u00e7lar\u0131 iki hafta i\u00e7inde %15&#8217;lik bir ralliyi tetikledi<\/li>\n<li>A\u011fustos 2024: Klinik deneme sonu\u00e7lar\u0131 tek g\u00fcnde %22&#8217;lik s\u0131\u00e7rama yaratt\u0131<\/li>\n<li>May\u0131s 2024: Olumlu Faz 3 verileri b\u00fcy\u00fck bir %150 art\u0131\u015fa neden oldu<a href=\"https:\/\/www.genengnews.com\/topics\/drug-discovery\/stockwatch-after-fda-approval-analysts-predict-blockbuster-sales-for-insmed-drug\/\">(GEN News)<\/a><\/li>\n<li>Kas\u0131m 2023: Ortakl\u0131k duyurusu %8 kazan\u00e7 sa\u011flad\u0131<\/li>\n<li>A\u011fustos 2023: FDA ba\u015fvuru haberi %12 momentum yaratt\u0131<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: olumlu klinik ve d\u00fczenleyici haberler patlay\u0131c\u0131 hareketler yarat\u0131rken, kazan\u00e7 raporlar\u0131 s\u00fcrd\u00fcr\u00fclebilir momentum sa\u011flar.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden Zaferine<\/h3>\n<p>INSM&#8217;nin \u015eubat 2025&#8217;ten bu yana yolculu\u011fu ola\u011fan\u00fcst\u00fc oldu. Hisse bu d\u00f6nemde <strong>%37.73<\/strong> de\u011fer kazand\u0131<a href=\"https:\/\/www.barchart.com\/stocks\/quotes\/insm\/performance\">(Barchart)<\/a>, ancak as\u0131l hikaye dramatik toparlanmada yat\u0131yor:<\/p>\n<ul>\n<li><strong>\u015eubat-Mart 2025<\/strong>: $85-95 aral\u0131\u011f\u0131nda i\u015flem g\u00f6rerek taban olu\u015fturdu<\/li>\n<li><strong>9 Nisan 2025<\/strong>: D\u00f6nemin en d\u00fc\u015f\u00fck seviyesi olan $60.40&#8217;a geriledi\u2014maksimum korku an\u0131<\/li>\n<li><strong>May\u0131s-Haziran 2025<\/strong>: $75-85 aral\u0131\u011f\u0131na istikrarl\u0131 toparlanma<\/li>\n<li><strong>Temmuz 2025<\/strong>: $95 \u00fczeri k\u0131r\u0131l\u0131m, momentum art\u0131yor<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: FDA onay kataliz\u00f6r\u00fc hisseyi mevcut $131.88 seviyesine f\u0131rlatt\u0131<\/li>\n<\/ul>\n<p>Nisan dip seviyesinden itibaren hisse inan\u0131lmaz bir <strong>%84.21<\/strong> y\u00fckseldi<a href=\"https:\/\/www.barchart.com\/stocks\/quotes\/insm\/performance\">(Barchart)<\/a>, kataliz\u00f6r odakl\u0131 biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n g\u00fcc\u00fcn\u00fc g\u00f6steriyor.<\/p>\n<h3>Bu Toparlanman\u0131n \u00d6nemi<\/h3>\n<p>V \u015feklindeki desen g\u00fc\u00e7l\u00fc kurumsal g\u00fcveni i\u015faret ediyor. Biyoteknoloji hisseleri diplerden b\u00f6yle sert s\u0131\u00e7rad\u0131\u011f\u0131nda, genellikle ak\u0131ll\u0131 paran\u0131n b\u00fcy\u00fck bir geli\u015fmenin yakla\u015ft\u0131\u011f\u0131n\u0131 bildi\u011fi anlam\u0131na gelir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 (Y\u0131l Sonu)<\/strong>: $145-160<br \/> Son FDA onay\u0131 \u00e7eyreklik gelir b\u00fcy\u00fcmesini desteklemeli, analistler ortalama hedefi <strong>$139.31<\/strong> olarak tahmin ediyor<a href=\"https:\/\/stockanalysis.com\/stocks\/insm\/forecast\/\">(StockAnalysis)<\/a>. Anahtar tarih 30 Ekim&#8217;deki 3. \u00e7eyrek kazan\u00e7lar\u0131\u2014g\u00fc\u00e7l\u00fc re\u00e7ete say\u0131lar\u0131 fiyat\u0131 \u00fcst seviyelere ta\u015f\u0131yabilir.<\/li>\n<li><strong>2026<\/strong>: $180-210<br \/> BRINSUPRI&#8217;nin tam y\u0131l ticarile\u015ftirilmesi ve Avrupa ile \u0130ngiltere&#8217;de uluslararas\u0131 lansmanlar. \u0130lac\u0131n tahmini $5 milyar zirve sat\u0131\u015f potansiyelinin yar\u0131s\u0131n\u0131 bile yakalamas\u0131 durumunda<a href=\"https:\/\/www.genengnews.com\/topics\/drug-discovery\/stockwatch-after-fda-approval-analysts-predict-blockbuster-sales-for-insmed-drug\/\">(GEN News)<\/a>, hisse \u00f6nemli \u00f6l\u00e7\u00fcde yeniden de\u011ferlenmeli.<\/li>\n<li><strong>2028<\/strong>: $250-300<br \/> Bu noktada birden fazla \u00fcr\u00fcn gelir katk\u0131s\u0131 sa\u011flamal\u0131. Akci\u011fer hipertansiyonu i\u00e7in geli\u015ftirdikleri TPIP adl\u0131 ila\u00e7 ticarile\u015febilir ve ek gelir kaynaklar\u0131 yaratabilir.<\/li>\n<li><strong>2030<\/strong>: $350-400+<br \/> K\u00fcresel geni\u015fleme ve mevcut ila\u00e7lar i\u00e7in potansiyel yeni endikasyonlar. Uygulama g\u00fc\u00e7l\u00fc kal\u0131rsa, INSM milyarlarca dolarl\u0131k gelir \u015firketi olabilir.<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM \u00f6nerisi. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 takip etmeli.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Pipeline\u2019daki herhangi bir aksama hisseyi olumsuz etkileyebilir<\/li>\n<li><strong>D\u00fczenleyici engeller<\/strong>: Uluslararas\u0131 onaylarda gecikmeler veya k\u0131s\u0131tlamalar olabilir<\/li>\n<li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri \u00fcst\u00fcn tedaviler geli\u015ftirebilir<\/li>\n<li><strong>Nakit t\u00fcketimi<\/strong>: 2025 2. \u00e7eyrekte 321.7 milyon $ net zarar bildirdiler<a href=\"https:\/\/www.prnewswire.com\/news-releases\/insmed-reports-second-quarter-2025-financial-results-and-provides-business-update-302523543.html\">(PR Newswire)<\/a><\/li>\n<li><strong>Piyasa volatilitesi<\/strong>: Biyoteknoloji hisseleri genellikle \u00f6ng\u00f6r\u00fclemezdir<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>FDA onay\u0131 al\u0131nd\u0131<\/strong>: BRINSUPRI art\u0131k ticari olarak mevcut<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>: Haziran 2025 itibar\u0131yla 1.9 milyar $<a href=\"https:\/\/www.prnewswire.com\/news-releases\/insmed-reports-second-quarter-2025-financial-results-and-provides-business-update-302523543.html\">(PR Newswire)<\/a><\/li>\n<li><strong>Gelir b\u00fcy\u00fcmesi<\/strong>: ARIKAYCE i\u00e7in y\u0131ll\u0131k %11-17 b\u00fcy\u00fcme \u00f6ng\u00f6r\u00fcl\u00fcyor<\/li>\n<li><strong>Analist deste\u011fi<\/strong>: 19 analistten 18\u2019i Al veya G\u00fc\u00e7l\u00fc Al derecelendirmesi veriyor<a href=\"https:\/\/stockanalysis.com\/stocks\/insm\/forecast\/\">(StockAnalysis)<\/a><\/li>\n<li><strong>Piyasa m\u00fcnhas\u0131rl\u0131\u011f\u0131<\/strong>: Bron\u015fektazi tedavisinde ilk hareket eden avantaj\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5\u2019inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Ortalama maliyetle al\u0131m yap\u0131n<\/strong>: T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a al\u0131n<\/li>\n<li><strong>30 Ekim i\u00e7in uyar\u0131 kurun<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 m\u00fckemmel giri\u015f noktas\u0131 olabilir<\/li>\n<li><strong>Re\u00e7ete verilerini takip edin<\/strong>: Ayl\u0131k re\u00e7ete say\u0131lar\u0131 kritik olacak<\/li>\n<li><em>Deneyimli yat\u0131r\u0131mc\u0131lardan esprili tavsiye<\/em>: &#8220;Biyoteknoloji hisseleriyle ticaret yapmak fl\u00f6rt etmek gibidir\u2014bazen peri masal\u0131 sonu ya\u015fars\u0131n\u0131z, bazen de d\u00fc\u011f\u00fcn salonunda kal\u0131rs\u0131n\u0131z. Her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 $131.88 (25 A\u011fustos itibar\u0131yla) kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015finizi verin<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 takip edin<\/td>\n<td>\u00d6nemli hareketli ortalamalar i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Uygun?<\/h3>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece $5<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>\u2014herhangi bir kimlik belgesini y\u00fckleyip hemen i\u015flem yapmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto para, e-c\u00fczdanlar ve banka kartlar\u0131 dahil<\/li>\n<li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131 m\u00fcmk\u00fcn<\/strong>\u2014INSM gibi pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Insmed: Nadir Hastal\u0131k Tedavisinde D\u00f6n\u00fc\u015f\u00fcm<\/h2>\n<p>Insmed ilgin\u00e7 bir kav\u015fakta duruyor. Klinik a\u015famadaki biyoteknoloji \u015firketinden FDA onay\u0131yla ticarile\u015fen bir \u015firkete ba\u015far\u0131l\u0131 bir ge\u00e7i\u015f yapt\u0131<a href=\"https:\/\/www.ajmc.com\/view\/brensocatib-becomes-first-fda-approved-therapy-for-bronchiectasis\">(AJMC)<\/a>. \u00d6zellikle yakla\u015f\u0131k 110.000 Amerikal\u0131y\u0131 etkileyen kistik fibrozis d\u0131\u015f\u0131 bron\u015fektazi gibi nadir akci\u011fer hastal\u0131klar\u0131na odaklanmalar\u0131, s\u0131n\u0131rl\u0131 rekabetin oldu\u011fu ancak hasta ihtiyac\u0131n\u0131n y\u00fcksek oldu\u011fu \u00f6zel bir ni\u015fte konumlanmalar\u0131n\u0131 sa\u011fl\u0131yor.<\/p>\n<p>\u015eirketin Haziran 2025&#8217;te ger\u00e7ekle\u015ftirdi\u011fi 750 milyon dolarl\u0131k halka arz<a href=\"https:\/\/investor.insmed.com\/2025-06-11-Insmed-Announces-Pricing-of-750-Million-Public-Offering-of-Common-Stock\">(Insmed Investor)<\/a>, BRINSUPRI&#8217;nin ticarile\u015ftirilmesi i\u00e7in yeterli kaynak sa\u011flarken di\u011fer pipeline varl\u0131klar\u0131n\u0131n geli\u015ftirilmesine devam edilmesini m\u00fcmk\u00fcn k\u0131ld\u0131.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Insmed&#8217;in BRINSUPRI&#8217;si, analistlerin bekledi\u011finden %10 daha y\u00fcksek olan y\u0131ll\u0131k 88.000 $&#8217;l\u0131k premium bir fiyat etiketiyle onay ald\u0131<a href=\"https:\/\/www.genengnews.com\/topics\/drug-discovery\/stockwatch-after-fda-approval-analysts-predict-blockbuster-sales-for-insmed-drug\/\">(GEN News)<\/a>. Bu fiyatlama g\u00fcc\u00fc, piyasan\u0131n yenilik\u00e7i nadir hastal\u0131k tedavilerine verdi\u011fi \u00f6nemli de\u011feri g\u00f6steriyor.<\/p>\n"},"faq":[{"question":"Insmed Incorporated hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir i\u015flem platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, g\u00fcncel fiyat\u0131 kontrol edin, limit emirleri kullanarak sipari\u015f verin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak takip edin."},{"question":"Insmed hisselerinin g\u00fcncel fiyat\u0131 nedir?","answer":"25 A\u011fustos 2025 itibar\u0131yla Insmed hisseleri NASDAQ'ta $131.88 fiyat\u0131yla i\u015flem g\u00f6rmektedir."},{"question":"Insmed'in FDA onay\u0131n\u0131n hisse fiyat\u0131na etkisi nedir?","answer":"FDA onay\u0131 sonras\u0131 hisse %4.6 art\u0131\u015f g\u00f6stererek $118.09 seviyesine y\u00fckselmi\u015f ve 52 haftal\u0131k en y\u00fcksek $120.50'yi g\u00f6rm\u00fc\u015ft\u00fcr."},{"question":"Insmed hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"2025 sonunda $145-160, 2026'da $180-210, 2028'de $250-300 ve 2030'da $350-400+ seviyeleri \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Insmed hisselerine yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131d\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici engeller, rekabet, y\u00fcksek nakit t\u00fcketimi ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Insmed Incorporated hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir i\u015flem platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, g\u00fcncel fiyat\u0131 kontrol edin, limit emirleri kullanarak sipari\u015f verin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak takip edin."},{"question":"Insmed hisselerinin g\u00fcncel fiyat\u0131 nedir?","answer":"25 A\u011fustos 2025 itibar\u0131yla Insmed hisseleri NASDAQ'ta $131.88 fiyat\u0131yla i\u015flem g\u00f6rmektedir."},{"question":"Insmed'in FDA onay\u0131n\u0131n hisse fiyat\u0131na etkisi nedir?","answer":"FDA onay\u0131 sonras\u0131 hisse %4.6 art\u0131\u015f g\u00f6stererek $118.09 seviyesine y\u00fckselmi\u015f ve 52 haftal\u0131k en y\u00fcksek $120.50'yi g\u00f6rm\u00fc\u015ft\u00fcr."},{"question":"Insmed hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"2025 sonunda $145-160, 2026'da $180-210, 2028'de $250-300 ve 2030'da $350-400+ seviyeleri \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Insmed hisselerine yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131d\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici engeller, rekabet, y\u00fcksek nakit t\u00fcketimi ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T19:29:59+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T19:29:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/\",\"name\":\"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"datePublished\":\"2025-08-25T19:29:59+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/","og_locale":"tr_TR","og_type":"article","og_title":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T19:29:59+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T19:29:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/","name":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","datePublished":"2025-08-25T19:29:59+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-insmed-incorporated\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Insmed Incorporated (INSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Insmed Incorporated (INSM) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":350499,"slug":"how-to-buy-insmed-incorporated","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Insmed Incorporated (INSM) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Insmed Incorporated (INSM)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-insmed-incorporated\/"},"pt_AA":{"locale":"pt_AA","id":350494,"slug":"how-to-buy-insmed-incorporated","post_title":"Como comprar a\u00e7\u00f5es da Insmed Incorporated (INSM) - Investimento em a\u00e7\u00f5es da Insmed Incorporated (INSM)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-insmed-incorporated\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/350495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=350495"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/350495\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334090"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=350495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=350495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=350495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}